Compare TransMedics Group Inc (TMDX) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Wynn Resorts, Limited — how do they compare? TransMedics Group Inc trades at $73.5 (market cap $2.54B), while Wynn Resorts, Limited trades at $94.75 (market cap $9.93B). The key difference: Wynn Resorts, Limited is far larger — about 3.9× TransMedics Group Inc's market cap, and Wynn Resorts, Limited pays a 1.05% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WYNN | |
|---|---|---|
Market Cap | $2.54B | $9.93B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $133.34 |
52-Week Low | $61.99 | $94.78 |
Enterprise Value | $2.94B | $20.29B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Wynn Resorts (WYNN) trades at $94.63, down 2.08% today, amid a bearish technical signal with recent earnings misses. The company maintains strong revenue growth with $7.14B in 2025, though net margins have compressed to 4.58%. Recent news highlights operational awards and Q2 2026 earnings anticipation. Technical indicators show support near $93-$95 with resistance at $97-$99, while RSI levels suggest neutral momentum.
Outlook remains mixed: analyst consensus is bullish with a $135.50 price target (64% buy ratings), but high debt ($10.5B long-term) and margin pressure pose risks. The stock offers potential upside if Macau and Las Vegas momentum sustains, though geopolitical and competitive headwinds require monitoring. Near-term catalysts include Q2 earnings on August 4, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
